Association between IRF6 and nonsyndromic cleft lip with or without cleft palate in four populations by 諛뺣퀝�쑄 & 吏��꽑�븯
Association between IRF6 and nonsyndromic cleft lip with or
without cleft palate in four populations
Ji Wan Park, PhD1, Iain McIntosh, PhD2, Jacqueline B. Hetmanski, MS1, Ethylin Wang Jabs,
MD2,3, Craig A. Vander Kolk, MD3, Yah-Huei Wu-Chou, MD4, Philip K. Chen, MD4, Samuel S.
Chong, PhD5, Vincent Yeow, MD6, Sun Ha Jee, PhD7, Beyoung Yun Park, MD8, M. Daniele
Fallin, PhD1, Roxann Ingersoll, MHS1, Alan F. Scott, PhD2, and Terri H. Beaty, PhD1
1Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University,
Baltimore, Maryland 2McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University,
Baltimore, Maryland 3Department of Surgery, School of Medicine, Johns Hopkins University,
Baltimore, Maryland 4Department of Medical Research and Craniofacial Center, Chang Gung
Memorial Hospital, Taoyuan, Taiwan 5Department of Pediatrics, Yong Loo Lin School of Medicine,
National University of Singapore, Singapore 6KK Women’s and Children’s Hospital, Singapore
7Department of Epidemiology, Graduate School of Public Health, Yonsei University, Seoul, Korea
8Department of Plastic Surgery, College of Medicine, Yonsei University, Seoul, Korea
Abstract
Purpose—The interferon regulatory factor 6 (IRF6), the gene that causes van der Woude syndrome
has been shown to be associated with nonsyndromic cleft lip with or without palate in several
populations. This study aimed to confirm the contribution of IRF6 to cleft lip with or without palate
risk in additional Asian populations.
Methods—A set of 13 single nucleotide polymorphisms was tested for association with cleft lip
with or without palate in 77 European American, 146 Taiwanese, 34 Singaporean, and 40 Korean
case-parent trios using both the transmission disequilibrium test and conditional logistic regression
models.
Results—Evidence of linkage and association was observed among all four populations; and two
specific haplotypes [GC composed of rs2235373-rs2235371 (p.V274I) and AAG of rs599021-
rs2235373-rs595918] showed the most significant over- and undertransmission among Taiwanese
cases (P = 9 × 10−6 and P = 5 × 10−6, respectively). The AGC/CGC diplotype composed of rs599021-
rs2235373-rs2013162 showed almost a 7-fold increase in risk among the Taiwanese sample (P <
10−3). These results confirmed the contribution of this gene to susceptibility of oral clefts across
different populations; however, the specific single nucleotide polymorphisms showing statistical
significance differed among ethnic groups.
Conclusion—The high-risk genotypes and diplotypes identified here may provide a better
understanding of the etiological role of this gene in oral clefts and potential options for genetic
counseling.
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Nonsyndromic cleft lip with or without cleft palate (CL/P) is one of the most common birth
defects with the birth prevalence being highest in Asian (2/1000 live births), intermediate in
European (1/1000 live births), and lowest in African populations (0.4/1000 live births). CL/P
is a complex disease with both genetic and environmental risk factors.1 Mutations in the
interferon regulatory factor 6 gene (IRF6) located on chromosome 1q32.3-q41 are responsible
for a majority of van der Woude syndrome (VWS) cases. VWS is an autosomal dominant
syndrome that includes an oral cleft and pits on the lower lip in approximately 85% of cases.
Fifteen percent of VWS cases have an isolated cleft with no lip pits and are clinically
indistinguishable from nonsyndromic CL/P.2 The GATA124F08 marker located 1Mb from
IRF6 has shown a significant heterogeneity LOD (1.15) with α = 0.45,3 and an anonymous
marker (D1S205) in IRF6 has yielded significant evidence of linkage and linkage
disequilibrium (LD) in 106 nonsyndromic CL/P trios.4 Recently, strong evidence of
overtransmission of the G allele at the IRF6 c.820G>A marker (rs2235371) was found in CL/
P case-parent trios from Asia and South America,5 and a significantly higher frequency of the
GG genotype was observed among 192 Thai CL/P cases compared with controls (odds ratio
= 1.67).6 This variant creates a valine→isoleucine substitution at amino acid 274 (p.V274I)
in the protein-binding domain [the Smad-interferon regulatory factor binding domain (SMIR)]
of IRF6, but the A allele is rare in white populations. Analysis of seven other single nucleotide
polymorphisms (SNPs) in and around IRF6 has shown several distinct haplotypes
demonstrating altered transmission in Io-wan and Danish trios.5 Confirmatory studies using
Italian, European-American, and Belgian CL/P families, respectively, have strengthened the
evidence that IRF6 is important in the etiology of nonsyndromic oral clefts.7–9 Risk of CL/P
associated with particular variants in IRF6 may differ among ethnic groups, however. Here,
we evaluated 13 SNPs in and around IRF6 to test for association with nonsyndromic CL/P in
77 European-American (including five incomplete trios), 146 (three incomplete trios) and 34
(11 incomplete trios) Han Chinese trios from Taiwan and Singapore, respectively, plus 40 (two
incomplete trios) Korean CL/P trios. Expression of IRF6 in human craniofacial structures was
also determined using publicly available data.
MATERIALS AND METHODS
Subjects
Infants born with isolated, nonsyndromic CL/P and their parents were ascertained through
treatment centers in Maryland (Johns Hopkins University and University of Maryland), Taiwan
(Chang Gung Memorial Hospital), Singapore (KK Women’s and Children’s Hospital), and
Korea (Yonsei University Medical Center), respectively, under a protocol approved by the
institutional review board at each institution as part of an international study of oral clefts.
After informed consent was obtained from parents, ethnicity and other data were obtained
through structured interviews.10 Both cases and parents provided blood samples.
SNP selection and genotyping
SNP markers in and around IRF6 were identified from the literature and the dbSNP database
(http://www.ncbi.nlm.nih.gov/projects/SNP/) using a NorthStar Searchlet program (Genetic
Software Innovations, Inc., Cicero, NY). A final set of 13 SNPs were chosen based on the
criteria of high “design scores” as provided by Illumina, Inc. (San Diego, CA), heterozygosity
>0.1, and HapMap validation (www.hapmap.org/index.html.en). The final marker set included
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the rs2235371 and rs2013162, which previously showed significant associations in Asians and
Europeans, respectively (Fig. 1). Primers for each SNP were synthesized using the Oligator
technology by Illumina, Inc. as part of an oligo pool for the BeadLab 1000 system. Genomic
DNA samples were prepared from peripheral blood lymphocytes by the protein precipitation
method described previously11 and genotyped for SNP markers using the Golden Gate
chemistry on Sentrix Array Matrices (Illumina, Inc.) at the Johns Hopkins SNP Center.12 The
average distance between neighboring markers was 1.53 kb (based on the Build 36.1 of
dbSNP). Two duplicates and four CEPH control DNA samples were included to evaluate
genotyping consistency.
Statistical analysis
Within each population, the minor allele frequency (MAF), heterozygosity, and a χ2 test for
Hardy-Weinberg equilibrium (HWE) at each SNP were computed among parents. Pairwise
LD was computed as both D′ and r2 for all SNPs using the Haploview program
(http://www.broad.mit.edu/mpg/haploview/index.php/).13,14 Individual SNPs and sliding
windows of haplotypes consisting of two, three, four, and five SNPs were tested using the
family-based association test program (http://www.biostat.harvard.edu/fbat/default.html).15
Empirical P values for observed versus expected transmission were obtained using the
permutation option and these are presented as −log10 P values.16 A Web interface (SNPSpD)
was used to perform the spectral decomposition correction for multiple comparisons
(http://genepi.qimr.edu.au/general/daleN/SNPSpD/).17 Genotypic odds ratios (GORs) for
heterozygotes and homozygotes were calculated separately for individual SNPs as well as for
diplotypes consisting of two or three SNP haplotypes yielding statistical significance. GORs
were obtained from conditional logistic regression models for matched sets consisting of the
case and three “pseudosib” controls derived from the parental mating type using publicly
available subroutines in the STATA software package
(http://www-gene.cimr.cam.ac.uk/clayton/software/stata/).
Gene expression analysis
Expression of IRF6 in human craniofacial structures relevant to normal palate and lip
development was determined using data obtained from the Craniofacial and Oral Gene
Expression Network (COGENE) consortium (http://hg.wustl.edu/COGENE/). Data from
seven serial analysis of gene expression (SAGE) libraries were used to assess gene expression
patterns in different human embryonic tissues (i.e., 26-day-old human embryonic tissue, 4-
week anterior rhombomere, 4-week posterior rhombomere, 4-week frontonasal prominence,
5-week frontonasal prominence, 6-week mandible, and 8.5-week upper lip).18
RESULTS
Proband gender for the four groups of case-parent trios is shown in Appendix Table A1
(available online at www.geneticsinmedicine.org). Examining duplicated samples revealed a
very high reproducibility for genotypes (99.98%). Minor allele frequencies for rs2235371 and
rs3753517 were too low to be informative in the Maryland samples (MAF <0.005 for both),
and only 60% of genotypes were called at rs2294408 in the Singapore and Korean samples.
All remaining SNPs gave no evidence of deviating from HWE (data not shown). Among the
13 SNPs, five groups of markers (rs599021-rs861019, rs2073485-rs2235373, rs2235371-
rs3753517, rs674433-rs595918, and rs2013162-rs2236907-rs2294408-rs2073487-rs1005287)
showed virtually complete LD (D′ = 1 and r2 > 0.8) in all four populations, so markers within
each block became redundant (see Appendix Table A2 available online at
www.geneticsinmedicine.org). Consequently, one tagging marker was chosen from each of
these five groups (rs599021, rs2235373, rs2235371, rs595918, and rs2013162) to represent
haplotypes showing significant transmission distortion and estimate GORs.
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TDT analyses for individual markers and haplotypes
In Figure 1, only empirical P values <0.10 from the transmission disequilibrium test (TDT)
are presented for haplotypes, whereas all empirical P values for the 13 individual SNPs in each
of the four populations are presented. TDT results for individual SNPs showing significant
evidence of linkage and LD among the four samples of CL/P trios are summarized in Table 1.
Two SNPs, rs2073485 and rs2235373, which were in complete LD with one another (both D
′ and r 2 = 1), yielded highly significant P values for both single marker and haplotype analyses
among the 146 Taiwanese CL/P trios (P = 2 × 10−6 and lowest P < 10−6, respectively). In the
34 Singaporean trios, seven SNPs and their haplotypes yielded nominal significance (lowest
P=0.014). Haplotypes consisting of three SNPs (rs2235371, rs674433, and rs595918) yielded
nominal significance in the Maryland trios. In the Korean trios, most haplotypes, including
rs2294408, were statistically significant; however, only nine families were informative for this
marker. Experiment-wide significance thresholds required to keep the type I error rate at 5%
for samples from Maryland, Taiwan, Singapore, and Korea are P < 0.010, 0.013, 0.017, and
0.013, respectively, based on the spectral decomposition correction. Therefore, statistical
evidence observed among the Taiwanese, Singaporean, and Korean trios remained significant
after correcting for multiple comparisons.
In Table 2, the most common haplotype (AATGA) across five SNPs (rs599021, rs2235373,
rs2235371, rs595918, and rs2013162) showed significant undertransmission (P = 0.00051),
whereas two haplotypes, (A/C)GC(A/G)C, were significantly overtransmitted among
Taiwanese CL/P children. Interestingly, two-SNP haplotypes [e.g., AA for rs599021 and
rs2235373 (P=5 × 10−6) or GC composed of rs2235373 and rs2235371 (P = 9 × 10−6)] were
more informative than the three- or four-SNP haplotypes. Here, all alleles are reported on the
forward strand of the chromosome (NCBI build 36.1), although the gene is transcribed from
the reverse strand. Allele designations need to be reversed when compared with published
reports that used the transcription strand as the reference.
Genotypic and diplotypic odds ratios
As shown in Table 3, G/G and C/C homozygotes at rs2235373 and rs2013162 had a
significantly increased risk of being CL/P cases [GOR = 4.94 and 3.78, 95% confidence interval
(CI) = 2.43–10.04 and 1.93–7.41, respectively], whereas C/C, C/C, and A/A homozygotes at
rs599021, rs2235371, and rs595918 were more likely to be CL/P cases compared with
reference homozygotes among Taiwanese trios (GOR = 2.92, 2.75, and 3.20, respectively, and
95% CI: 1.15–7.42, 1.37–5.52, and 1.15–8.90, respectively), although the global P value for
the conditional logistic model of rs595918 was not significant. The C/C genotype at rs2013162
increased the risk of being a CL/P case among Singaporean trios (GOR = 6.88, 95% CI: 1.17–
40.34).
To determine diplotype specific risks in the Taiwanese trios, two-, three- and four-marker
models were tested as shown in Table 4. Diplotypes with frequency <4% were analyzed as a
single group. The AG/CG diplotype for rs599021 and rs2235373 showed the most increased
risk of being a CL/P case among all two-SNP diplotypes composed from the four SNPs
identified in Table 3 (i.e., 5.95 times higher than AA/AA, the reference diplotype group; 95%
CI: 2.53–13.99). Interestingly, the GOR for diplotypes that included A/C heterozygotes at
rs599021 and homozygotes for the high-risk allele at other loci showed the greatest risk. For
instance, the AGC/CGC diplotype showed a higher risk of being a CL/P (GOR = 6.99, 95%
CI: 2.70–18.06) than did the CGC/CGC diplotype (GOR = 3.70, 95% CI: 1.31–10.46). Using
data from the COGENE consortium, the IRF6 gene was found to be expressed in the 4-week
frontonasal prominence among seven SAGE libraries.
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DISCUSSION
Zucchero et al.5 showed strong evidence of overtransmission of the valine (V) allele at p.V274I
(rs2235371) in IRF6; however, the estimated attributable risk (11.6%) and the estimated 3-fold
increased recurrence risk among Filipino CL/P case-parent trios must be interpreted carefully
because it was assumed that carrying this allele was directly causal and uncorrelated with other
risk factors.6 This SNP is not highly polymorphic in Europeans, although Asians have allele
frequencies around 66% for the G allele (p.274V).9,19 Thus, subsequent studies in European-
derived populations focused on four SNPs (rs1319435, rs2013162, rs2235375, and rs2235543)
with higher heterozygosity levels. Scapoli et al.7 detected overtransmission of the G and C
alleles for markers rs2013162 and rs2235375 (P = 0.004 and P = 0.002, respectively) and all
haplotypes carrying these common alleles among 219 Italian CL/P trios (the GTGA haplotype
showed significant undertransmission, P = 0.0003). Blanton et al.8 detected overtransmission
of the C allele at rs2013162 (P = 0.05), and all haplotypes including the A allele at this marker
were significantly undertransmitted to cases (the lowest P = 0.002 for CAXT haplotype among
216 European-American families with CL/P). Ghassibé et al.9 observed transmission distortion
of the GG and TG haplotypes (P= 0.004 and P= 0.036, respectively) for two markers
(rs2013162 and rs2235543) and confirmed overtransmission of the G allele at rs2013162 (P =
0.01) in 195 Belgium families (this sample included some immigrant families from other
populations). Alleles were designated (T/G) for rs2013162 based on the 3′ to 5′ orientation of
this gene in some studies, whereas here these alleles are designated A/C based on their 5′ to 3′
orientation on the chromosome. Reported significance levels from these published studies did
not include corrections for multiple comparisons.
Initially, we analyzed 103 European-American trios, 171 and 66 Han Chinese trios from
Taiwan and Singapore, respectively, and 42 Korean trios with either CL/P or isolated cleft
plate (results not shown). When stratified by type of cleft, we found greater statistical
significance among CL/P groups, despite the smaller numbers, confirming the possibility of
etiologic heterogeneity (e.g., P = 3.6 × 10−5 vs. P = 2 × 10−6 at rs2235373 alone among all
171 Taiwanese trios vs. the 146 CL/P trios).
Two SNPs (rs2073485 and rs2235373), located next to, but not in LD with, the V274I variant,
yielded statistical significance for individual SNPs and haplotypes among Taiwanese trios,
even after correcting for multiple comparisons. In particular, the G allele at rs2235373
significantly increased the risk of being a CL/P case, whereas the A allele was underrepresented
among Taiwanese cases. Overtransmission of the C allele at rs2013162 (located in the fifth
exon of IRF6) was not confirmed here among European-American trios (from Maryland), in
contrast to three previously reported studies of European-derived populations. In our Han
Chinese populations (Taiwan and Singapore), the C allele at this synonymous SNP
significantly increased the risk of being a CL/P case, whereas haplotypes including the A allele
at the same marker were consistently undertransmitted to CL/P cases (Table 2).
This is the first study that has considered genotypic and diplotypic risks for specific SNP
markers in IRF6 particularly in Taiwanese, Singaporean, and Korean samples. However, the
number of Singaporean and Korean trios available may not be sufficient to detect SNPs with
weak or moderate effects on risk. Although the C allele at rs599021 was overtransmitted to
cases and C/C homozygotes showed an increased risk of being a CL/P case, C/A heterozygotes
seemed to be at higher risk when diplotypes were considered with other SNPs (Table 4). The
fact that mutations in IRF6 cause VWS, which usually includes CL/P, combined with
significant evidence of linkage and association with CL/P in our study and other case-parent
trio studies strongly suggests that IRF6 itself is a causal gene for CL/P, but not the only one.
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IRF6 is one of nine members of a family of transcription factors (IRFs) that share a highly
conserved helix-turn helix DNA-binding domain and a less conserved protein-binding domain.
These domains exert diverse functions including regulating host defense pathways.20–22 The
Irf6 gene was expressed in the ectoderm fusion forming the upper lip and primary palate in
both mouse and chick, but only in the developing secondary palate of the mouse (which fuses
as in humans).23 Similar expression patterns for IRF6 are also seen in human craniofacial
structures, although the biological function of IRF6 during development of the lip and palate
in humans remains uncertain.
Significant results observed from SNPs other than p.V274I (rs2235371) suggested that V274I
itself is not causal, but rather in LD with some causal mutation in IRF6. Patterns of LD between
SNPs and the SNPs that individually showed statistical significance differed across our sample
populations (see Appendix Table A2). However, our data confirm that the IRF6 gene is
associated with increased risk of CL/P, and thus the regions showing statistical evidence of
association (e.g., rs599021, rs2235373, rs2235371, and rs2013162 for two Chinese groups;
rs2294408 for Korean trios) should be searched further for causal variants. High-risk genotypes
and diplotypes identified here may provide a better understanding of the etiological role that
IRF6 plays in CL/P and could prove useful in genetic counseling, if these findings can be
confirmed in subsequent studies.
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Fig. 1.
Significance of individual single nucleotide polymorphisms (SNPs) and sliding window
haplotypes for the interferon regulatory factor 6 (IRF6) gene in four groups of nonsyndromic
cleft lip with or without cleft palate trios. The −log10 (empirical P value) for the overall χ2 test
for an individual SNP (vertical line) and for sliding windows of haplotypes of two to five SNPs
(horizontal lines) is presented. Nominal significance levels are denoted by gray lines (5%, 1%,
0.1%, 0.01%, and 0.001%).
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